Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 106   

Articles published

JNJ 102.31 +1.81 (1.80%)
price chart
Biogen Inc. Takes Aim at Johnson & Johnson
The launch of a biosimilar to Johnson & Johnson's (NYSE:JNJ) top-selling Remicade this year is a key goal of a joint venture between Biogen Inc. (NASDAQ:BIIB) and South Korea-based Samsung.
Developing vaccine for Zika to take time: Johnson & Johnson's Paul Stoffels
MUMBAI: A Zika vaccine may still be a long way off because of the complications involved in identifying the virus, which has so far not been studied by virologists, said Paul Stoffels, chief scientific officer of US drug maker Johnson & Johnson. "The ...
Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte ...
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment.
Johnson & Johnson, ViaCyte testing possible diabetes cure  Waterbury Republican American
Johnson & Johnson, ViaCyte Testing Type 1 Diabetes Cure  Cinema Blaze
Why Isn't Johnson & Johnson Making More Acquisitions?
A massive and uncharacteristically high cash stockpile has Johnson & Johnson's (NYSE:JNJ) management discussing how best to spend its money.
Johnson & Johnson CEO buys $9 million Manhattan condo
Alex Gorsky, the CEO of Johnson & Johnson, and his wife, Patricia, bought a $9 million condo at One Riverside Park, an Extell Development project at 50 Riverside Drive - well over its $8.86 million asking price, according to city property records.
A Cure for Diabetes Is Moving Closer Toward Reality
Johnson & Johnson JNJ -3.23% has joined forces with diabetes treatment company ViaCyte to speed the development of a stem-cell based cure, as first reported by the Associated Press.
One Big Threat to Johnson & Johnson's Future
In this video segment, Motley Fool healthcare contributor Todd Campbell and healthcare analyst Kristine Harjes discuss the looming biosimilar threat to Johnson & Johnson's multi-billion dollar autoimmune disease drug and why investors shouldn't worry ...
Johnson & Johnson: Watch Free Cash Flow, Not Earnings
Right off the bat, I will proclaim that I have long-term faith in Johnson & Johnson (NYSE:JNJ) as a sustainable company.
Will Johnson & Johnson (JNJ) Take M&A Action in 2016?  ETF Daily News
Johnson & Johnson (JNJ) Stock: Earnings In Focus  CNA Finance (press release)
Johnson & Johnson revenue tumbles as currency takes toll
Health giant Johnson & Johnson's revenue fell 2.4% to $17.8 billion in the fourth quarter, compared with a year earlier, as currency rates and a medical devices slump continued to take a toll.
J&J sales fall on strong dollar  CNBC
Johnson & Johnson Can Heal Your Sick Portfolio  Barron's
What Johnson & Johnson's Restructuring Means
Motley Fool healthcare contributor Todd Campbell and healthcare analyst Kristine Harjes discuss Johnson & Johnson's (NYSE:JNJ) decision to restructure its multi-billion dollar medical device business. What is the company planning for the division, and ...